Biogen IDEC Inc Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (54)

Latest Posts

About This Stock More About This Stock
JPMorgan Healthcare Day One Notes: Weak Start Despite Positive Updates
Article By: Rod Raynovich
Tuesday, January 9, 2018 2:59 PM EST
Biotech stocks abruptly sold off at the market open yesterday with the XBI down 2% to the $85.31 level and the IBB down 1.33% to $108.37.
In this article: IBB, XBI, BIIB, CELG, GILD
Read
Biotech Year One: A Year Of Trials Tribulations And Discovery
Article By: Kieran O'Dea
Monday, December 25, 2017 8:24 AM EST
The biotech market is its own beast, derived from the aggregate opinions and knowledge of the mainstream thought. The market has a binary, linear, and simplistic approach to trial results ignoring the context in which each trial is conducted.
In this article: IBB, XBI, XPH, SPY, TEVA, AGN, JNJ, MYL, BMY, BIIB, PFE, MRK, INCY
Read
Biogen Price Target Raised To $420 From $355 At Nomura Instinet
Article By: The Fly
Friday, December 22, 2017 8:08 AM EST
Nomura Instinet analyst Christopher Marai yesterday raised his price target for Biogen to $420 following a pipeline "deep dive."
In this article: BIIB
Read
Credit Suisse Upgrades Biogen With 'Significant Turnaround' Underway
Article By: The Fly
Wednesday, December 20, 2017 7:08 AM EST
Credit Suisse analyst Alethia Young upgraded Biogen to Outperform from Neutral and raised her price target for the shares to $385 from $321. The stock closed yesterday up $1.07 to $327.02.
In this article: BIIB Also: GILD
Read
BMO Argues For Biogen As Most Logical Takeover Target For Pfizer
Article By: The Fly
Monday, November 13, 2017 2:15 PM EST
Commenting on "significant market speculation" that Pfizer is preparing to execute a large M&A deal, BMO Capital analyst Alex Arfaei argued that he sees a strong strategic rationale for a merger with Biogen.
In this article: PFE, BIIB Also: BMY, MRK, AZN, LLY
Read

PARTNER HEADLINES

Latest Tweets for $BIIB

No tweets yet!

$BIIB

Alert: Alzheimer’s Drug Fails In Clinical Trial - Stocks Sink
Craig Newman 11/24/2016 5:28:00 AM

What are the chances of $BIIB and $TSRO being bought out? They have long been targets, or at least rumored to be, for consolidation.

1 to 1 of 1 comments